BASIC RESEARCH
miR-630 functions as a tumor oncogene in renal cell carcinoma
 
More details
Hide details
 
Submission date: 2014-07-04
 
 
Final revision date: 2014-09-25
 
 
Acceptance date: 2014-09-27
 
 
Online publication date: 2016-05-18
 
 
Publication date: 2016-05-16
 
 
Arch Med Sci 2016;12(3):473-478
 
KEYWORDS
TOPICS
ABSTRACT
Introduction: MicroRNAs (miRNAs) are non-coding RNAs that regulate multiple cell processes during cancer progression. Renal cell carcinoma (RCC) is a malignancy with a poor prognosis. In this study, we aimed to investigate the roles of miR-630 in RCC progression.
Material and methods: Expression of miR-630 was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) in four renal cancer cell lines (786-O, ACHN, Caki-1, and Caki-2) and one normal human proximal tubule epithelial cell line (HK-2). Next, miR-630 inhibitor was used to inhibit miR-630 expression in 786-O cells. Finally, its effects on cell proliferation, apoptosis, migration, and invasion were evaluated.
Results: The expression level of miR-630 was higher in renal cancer cell lines 786-O, ACHN, Caki-1, and Caki-2 than that in the normal renal cell line HK-2 (p < 0.05). Furthermore, a proliferation assay, apoptosis assay, migration assay and invasion assay were performed, and the results showed that down-regulation of miR-630 expression by miR-630 inhibitor significantly inhibited cell proliferation, migration, and invasion, which meanwhile induced cell apoptosis of the renal cancer cell line 786-O.
Conclusions: This is the first time that miR-630 expression has been shown to be associated with renal cancer progression, and down-regulation of miR-630 can inhibit tumor progression, which provides a potential therapeutic target for renal cancer treatment.
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top